Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms

Gram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent an increasing challenge due to emergence of antimicrobial resistance. Escherichia coli and Pseudomonas aeruginosa are among the most common cause of GN-PJI and ciprofloxacin is the first-line antibiotic. Due t...

Full description

Bibliographic Details
Main Authors: Lei Wang, Mariagrazia Di Luca, Tamta Tkhilaishvili, Andrej Trampuz, Mercedes Gonzalez Moreno
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2019.02522/full
id doaj-7076c73446144e458a50c74e7d98fc63
record_format Article
spelling doaj-7076c73446144e458a50c74e7d98fc632020-11-25T01:50:35ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2019-11-011010.3389/fmicb.2019.02522489023Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa BiofilmsLei Wang0Lei Wang1Mariagrazia Di Luca2Tamta Tkhilaishvili3Tamta Tkhilaishvili4Andrej Trampuz5Andrej Trampuz6Mercedes Gonzalez Moreno7Mercedes Gonzalez Moreno8Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyCenter for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies, Charité – Universitätsmedizin Berlin, Berlin, GermanyGram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent an increasing challenge due to emergence of antimicrobial resistance. Escherichia coli and Pseudomonas aeruginosa are among the most common cause of GN-PJI and ciprofloxacin is the first-line antibiotic. Due to emergence of fluoroquinolone resistance, we evaluated in vitro the activity of fosfomycin, ciprofloxacin, and gentamicin, alone and in combinations, against E. coli and P. aeruginosa biofilms. Conventional microbiological tests and isothermal microcalorimetry were applied to investigate the anti-biofilm activity of the selected antibiotics against standard laboratory strains as well as clinical strains isolated from patients with prosthetic joint associated infections. The biofilm susceptibility to each antibiotic varied widely among strains, while fosfomycin presented a poor anti-biofilm activity against P. aeruginosa. Synergism of two-pair antibiotic combinations was observed against different clinical strains from both species. Highest synergism was found for the fosfomycin/gentamicin combination against the biofilm of E. coli strains (75%), including a gentamicin-resistant but fosfomycin-susceptible strain, whereas the gentamicin/ciprofloxacin combination presented synergism with higher frequency against the biofilm of P. aeruginosa strains (71.4%). A hypothetical bacteriolysis effect of gentamicin could explain why combinations with this antibiotic seem to be particularly effective. Still, the underlying mechanism of the synergistic effect on biofilms is unknown. In conclusion, combinatorial antibiotic application has shown to be more effective against biofilms compared to monotherapy. Further in vivo and clinical studies are essential to define the potential treatment regimen based on our results.https://www.frontiersin.org/article/10.3389/fmicb.2019.02522/fullEscherichia coliPseudomonas aeruginosabiofilm-associated infectionantibiotic activitysynergismclinical isolates
collection DOAJ
language English
format Article
sources DOAJ
author Lei Wang
Lei Wang
Mariagrazia Di Luca
Tamta Tkhilaishvili
Tamta Tkhilaishvili
Andrej Trampuz
Andrej Trampuz
Mercedes Gonzalez Moreno
Mercedes Gonzalez Moreno
spellingShingle Lei Wang
Lei Wang
Mariagrazia Di Luca
Tamta Tkhilaishvili
Tamta Tkhilaishvili
Andrej Trampuz
Andrej Trampuz
Mercedes Gonzalez Moreno
Mercedes Gonzalez Moreno
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
Frontiers in Microbiology
Escherichia coli
Pseudomonas aeruginosa
biofilm-associated infection
antibiotic activity
synergism
clinical isolates
author_facet Lei Wang
Lei Wang
Mariagrazia Di Luca
Tamta Tkhilaishvili
Tamta Tkhilaishvili
Andrej Trampuz
Andrej Trampuz
Mercedes Gonzalez Moreno
Mercedes Gonzalez Moreno
author_sort Lei Wang
title Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
title_short Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
title_full Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
title_fullStr Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
title_full_unstemmed Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
title_sort synergistic activity of fosfomycin, ciprofloxacin, and gentamicin against escherichia coli and pseudomonas aeruginosa biofilms
publisher Frontiers Media S.A.
series Frontiers in Microbiology
issn 1664-302X
publishDate 2019-11-01
description Gram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent an increasing challenge due to emergence of antimicrobial resistance. Escherichia coli and Pseudomonas aeruginosa are among the most common cause of GN-PJI and ciprofloxacin is the first-line antibiotic. Due to emergence of fluoroquinolone resistance, we evaluated in vitro the activity of fosfomycin, ciprofloxacin, and gentamicin, alone and in combinations, against E. coli and P. aeruginosa biofilms. Conventional microbiological tests and isothermal microcalorimetry were applied to investigate the anti-biofilm activity of the selected antibiotics against standard laboratory strains as well as clinical strains isolated from patients with prosthetic joint associated infections. The biofilm susceptibility to each antibiotic varied widely among strains, while fosfomycin presented a poor anti-biofilm activity against P. aeruginosa. Synergism of two-pair antibiotic combinations was observed against different clinical strains from both species. Highest synergism was found for the fosfomycin/gentamicin combination against the biofilm of E. coli strains (75%), including a gentamicin-resistant but fosfomycin-susceptible strain, whereas the gentamicin/ciprofloxacin combination presented synergism with higher frequency against the biofilm of P. aeruginosa strains (71.4%). A hypothetical bacteriolysis effect of gentamicin could explain why combinations with this antibiotic seem to be particularly effective. Still, the underlying mechanism of the synergistic effect on biofilms is unknown. In conclusion, combinatorial antibiotic application has shown to be more effective against biofilms compared to monotherapy. Further in vivo and clinical studies are essential to define the potential treatment regimen based on our results.
topic Escherichia coli
Pseudomonas aeruginosa
biofilm-associated infection
antibiotic activity
synergism
clinical isolates
url https://www.frontiersin.org/article/10.3389/fmicb.2019.02522/full
work_keys_str_mv AT leiwang synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT leiwang synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT mariagraziadiluca synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT tamtatkhilaishvili synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT tamtatkhilaishvili synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT andrejtrampuz synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT andrejtrampuz synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT mercedesgonzalezmoreno synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
AT mercedesgonzalezmoreno synergisticactivityoffosfomycinciprofloxacinandgentamicinagainstescherichiacoliandpseudomonasaeruginosabiofilms
_version_ 1725001040665772032